All
Results: 36181-36192 of 63117

AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11






